Myovant Sciences (MYOV) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Myovant Sciences (NYSE:MYOV) from a sell rating to a hold rating in a report released on Wednesday.

Separately, Zacks Investment Research raised Myovant Sciences from a sell rating to a hold rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Myovant Sciences presently has a consensus rating of Hold and an average price target of $21.00.

How to Become a New Pot Stock Millionaire

Myovant Sciences stock opened at $21.20 on Wednesday. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $24.14. The company has a current ratio of 5.04, a quick ratio of 5.04 and a debt-to-equity ratio of 0.35.

Myovant Sciences (NYSE:MYOV) last released its quarterly earnings data on Tuesday, February 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.28). sell-side analysts predict that Myovant Sciences will post -2.35 EPS for the current fiscal year.

In other news, major shareholder Pharmaceuticals Interna Takeda bought 7,420,625 shares of the firm’s stock in a transaction on Monday, March 19th. The stock was acquired at an average price of $18.67 per share, with a total value of $138,543,068.75. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Holdings Ltd. Dexxon bought 1,110,015 shares of the firm’s stock in a transaction on Monday, April 2nd. The shares were purchased at an average cost of $20.27 per share, with a total value of $22,500,004.05. The disclosure for this purchase can be found here. Corporate insiders own 3.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in Myovant Sciences during the 3rd quarter valued at approximately $1,255,000. Ardsley Advisory Partners acquired a new stake in Myovant Sciences during the 4th quarter valued at approximately $1,272,000. Finally, JPMorgan Chase & Co. increased its position in Myovant Sciences by 18.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after purchasing an additional 14,203 shares during the period. 81.44% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3338441/myovant-sciences-myov-raised-to-hold-at-valuengine.html.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.35 EPS Expected for Darden Restaurants  This Quarter
$1.35 EPS Expected for Darden Restaurants This Quarter
BumbaCoin Reaches Market Cap of $124,516.00
BumbaCoin Reaches Market Cap of $124,516.00
AICHAIN  Reaches 1-Day Volume of $34,278.00
AICHAIN Reaches 1-Day Volume of $34,278.00
JobsCoin  Trading Down 37.7% Over Last Week
JobsCoin Trading Down 37.7% Over Last Week
$2.56 Billion in Sales Expected for Discover Financial Services  This Quarter
$2.56 Billion in Sales Expected for Discover Financial Services This Quarter
Zacks: Analysts Anticipate Dover Co.  to Post $1.15 Earnings Per Share
Zacks: Analysts Anticipate Dover Co. to Post $1.15 Earnings Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.